1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow GVV858: new trials by email Literature Review of GVV858 trials Research Report on GVV858
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors GVV858, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 205 | 2025-12-29 | 2026-10-09 |
Breast Neoplasms (1) · Prostatic Neoplasms (1)
Canada (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Singapore (1) · Spain (1) · Taiwan (1) · United States (1)
2025 (1)